FDA Clearance Tracker · P030002-S035
CRYSTALENS AND TRULIGN TORIC INTRAOCULAR LENSES (IOLS)
Last checked: Nov 20, 2026Latest source record: Mar 24, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Mar 24, 2016
Approved
Time to decision
266 days
Received Jul 2, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P030002-S035
- Device name
- CRYSTALENS AND TRULIGN TORIC INTRAOCULAR LENSES (IOLS)
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- Jul 2, 2015
- Decided
- Mar 24, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P030002
Device type
- Device type
- LENS, INTRAOCULAR, TORIC OPTICS (MJP)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site located at Bausch & Lomb, Incorporated, 21 Park Place Boulevard North, Clearwater, Florida 33759 as an alternate manufacturing facility for the Crystalens and Trulign IOLs.
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
P240005 · Decided Oct 10, 2024 · 216 days after receipt
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.